EA202091626A1 - Инъецируемые композиции тритерпеноидных противогрибковых соединений, инкапсулированных в липосомах - Google Patents

Инъецируемые композиции тритерпеноидных противогрибковых соединений, инкапсулированных в липосомах

Info

Publication number
EA202091626A1
EA202091626A1 EA202091626A EA202091626A EA202091626A1 EA 202091626 A1 EA202091626 A1 EA 202091626A1 EA 202091626 A EA202091626 A EA 202091626A EA 202091626 A EA202091626 A EA 202091626A EA 202091626 A1 EA202091626 A1 EA 202091626A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antifungal compounds
incapped
liposomes
fungal infections
triterpenoid
Prior art date
Application number
EA202091626A
Other languages
English (en)
Russian (ru)
Inventor
Раджешвар Мозерам
Original Assignee
Сайнексис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайнексис, Инк. filed Critical Сайнексис, Инк.
Publication of EA202091626A1 publication Critical patent/EA202091626A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
EA202091626A 2018-01-02 2018-12-21 Инъецируемые композиции тритерпеноидных противогрибковых соединений, инкапсулированных в липосомах EA202091626A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862612893P 2018-01-02 2018-01-02
PCT/US2018/067216 WO2019135954A1 (en) 2018-01-02 2018-12-21 Injectable compositions of triterpenoid antifungals encapsulated in liposomes

Publications (1)

Publication Number Publication Date
EA202091626A1 true EA202091626A1 (ru) 2020-09-22

Family

ID=65024141

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091626A EA202091626A1 (ru) 2018-01-02 2018-12-21 Инъецируемые композиции тритерпеноидных противогрибковых соединений, инкапсулированных в липосомах

Country Status (27)

Country Link
US (3) US20200338002A1 (cg-RX-API-DMAC7.html)
EP (2) EP4137123A1 (cg-RX-API-DMAC7.html)
JP (3) JP7378401B2 (cg-RX-API-DMAC7.html)
KR (1) KR102694692B1 (cg-RX-API-DMAC7.html)
CN (2) CN115998684A (cg-RX-API-DMAC7.html)
AU (1) AU2018399599B2 (cg-RX-API-DMAC7.html)
CA (1) CA3087176A1 (cg-RX-API-DMAC7.html)
DK (1) DK3735226T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091626A1 (cg-RX-API-DMAC7.html)
ES (1) ES2927051T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221295T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060400T2 (cg-RX-API-DMAC7.html)
IL (2) IL275758B2 (cg-RX-API-DMAC7.html)
LT (1) LT3735226T (cg-RX-API-DMAC7.html)
MA (1) MA51514A (cg-RX-API-DMAC7.html)
MD (1) MD3735226T2 (cg-RX-API-DMAC7.html)
MX (1) MX2020006992A (cg-RX-API-DMAC7.html)
PL (1) PL3735226T3 (cg-RX-API-DMAC7.html)
PT (1) PT3735226T (cg-RX-API-DMAC7.html)
RS (1) RS63687B1 (cg-RX-API-DMAC7.html)
SA (1) SA520412362B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006313WA (cg-RX-API-DMAC7.html)
SI (1) SI3735226T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200427T1 (cg-RX-API-DMAC7.html)
TW (2) TWI857944B (cg-RX-API-DMAC7.html)
UA (1) UA126096C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019135954A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7378401B2 (ja) * 2018-01-02 2023-11-13 サイネクシス,インコーポレーテッド リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
NZ589967A (en) * 2004-01-14 2012-07-27 Gilead Sciences Inc Lipid-based dispersions useful for drug delivery
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
CA2700530C (en) * 2007-09-28 2014-12-09 Merck Sharp & Dohme Corp. Antifungal agents
US8226965B2 (en) * 2008-04-25 2012-07-24 Nanobio Corporation Methods of treating fungal, yeast and mold infections
JP2011529038A (ja) * 2008-07-23 2011-12-01 ターゲッティド デリバリー テクノロジーズ リミテッド 真菌感染症の処置のための局所抗真菌製剤の投与方法
WO2010019204A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
PE20120923A1 (es) * 2009-03-30 2012-08-27 Eisai Randd Man Co Ltd Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo
PT3247711T (pt) * 2015-01-19 2022-05-16 Scynexis Inc Novos sais e polimorfos de scy-078
JP7378401B2 (ja) * 2018-01-02 2023-11-13 サイネクシス,インコーポレーテッド リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物

Also Published As

Publication number Publication date
KR20200105875A (ko) 2020-09-09
BR112020013448A2 (pt) 2020-12-01
US20230277455A1 (en) 2023-09-07
JP2025106349A (ja) 2025-07-15
AU2018399599A1 (en) 2020-07-16
UA126096C2 (uk) 2022-08-10
CA3087176A1 (en) 2019-07-11
IL275758B1 (en) 2025-03-01
SMT202200427T1 (it) 2022-11-18
JP2021508728A (ja) 2021-03-11
EP3735226A1 (en) 2020-11-11
EP3735226B1 (en) 2022-08-10
AU2018399599B2 (en) 2022-09-01
JP2024012452A (ja) 2024-01-30
TW202434242A (zh) 2024-09-01
TW201929853A (zh) 2019-08-01
DK3735226T3 (da) 2022-10-24
MA51514A (fr) 2021-04-07
KR102694692B1 (ko) 2024-08-14
CN111655237B (zh) 2023-02-03
WO2019135954A1 (en) 2019-07-11
MD3735226T2 (ro) 2023-03-31
SI3735226T1 (sl) 2022-11-30
JP7378401B2 (ja) 2023-11-13
EP4137123A1 (en) 2023-02-22
CN111655237A (zh) 2020-09-11
MX2020006992A (es) 2020-09-09
CN115998684A (zh) 2023-04-25
PL3735226T3 (pl) 2022-12-19
TWI857944B (zh) 2024-10-11
RS63687B1 (sr) 2022-11-30
IL318793A (en) 2025-04-01
PT3735226T (pt) 2022-09-20
US20250082574A1 (en) 2025-03-13
HUE060400T2 (hu) 2023-02-28
US20200338002A1 (en) 2020-10-29
LT3735226T (lt) 2022-11-10
HRP20221295T1 (hr) 2022-12-23
TWI862280B (zh) 2024-11-11
SG11202006313WA (en) 2020-07-29
NZ765771A (en) 2024-09-27
SA520412362B1 (ar) 2022-12-15
ES2927051T3 (es) 2022-11-02
IL275758B2 (en) 2025-07-01
IL275758A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
SA522433087B1 (ar) Sos1 مثبطات
SA522431915B1 (ar) Prmt5 مثبطات mta تعاونية مع
PH12017502092A1 (en) Topical pharmaceutical compositions
EP2582375A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF ADDICTION, PSYCHIATRIC DISORDERS, AND NEURODEGENERATIVE DISEASE
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
WO2018111315A8 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
MX388592B (es) Compuestos y metodos terapeuticos.
EA201591180A1 (ru) Составы ингибитора lfa-1
PH12021551232A1 (en) Haloallylamine compounds and application thereof
EA201992826A1 (ru) 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ
EA201790040A1 (ru) Паразитицидные композиции, содержащие индольные производные, способы их получения и их применение
MX2022011203A (es) Compuestos de 9-aminometil minociclina y usos de los mismos.
MX381311B (es) Método para el tratamiento de prurito y/o comezón.
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения
EA202191378A1 (ru) Активные сложноэфирные производные тестостерона, их композиции и применения
MX2020006992A (es) Composiciones inyectables de antifungicos triterpenoides encapsulados en liposomas.
EA201992413A1 (ru) Противогрибковые средства, используемые в комбинации
EA202090445A1 (ru) ПРОТИВОГРИБКОВЫЕ СРЕДСТВА С ПОВЫШЕННОЙ АКТИВНОСТЬЮ ПРИ КИСЛОМ pH
MX2021011253A (es) Moduladores de tdp-43.
MX381515B (es) Composición farmacéutica que comprende nebivolol con tasa de disolución mejorada
EA202091561A1 (ru) Фармацевтическая композиция, содержащая фармацевтически приемлемую кислотно-аддитивную соль леналидомида
EA201990443A1 (ru) Новое применение n,n-бис-2 -меркаптоэтилизофталамида
UY39466A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis